Literature DB >> 6117576

Single-dose study of nabilone in anxious volunteers.

R M Glass, E H Uhlenhuth, F W Hartel, C R Schuster, M W Fischman.   

Abstract

The effects of single oral doses of nabilone, a synthetic cannabinoid, were studied in eight anxious volunteer subjects. Each subject had two exposures to placebo and three dose levels of nabilone at one-week intervals in a single-blind balanced Latin-square design after the nabilone dose range was determined by each subject's response to a test dose. Heart rate and blood pressure were monitored. The Profile of Mood States (POMS), a self-rating adjective checklist, was used as the quantitative measure of subjective effects. Four subjects performed a continuous avoidance procedure. High doses (4 or 5 mg) of nabilone produced orthostatic hypotension in these subjects. Mild dose-related increases in heart rate also occurred. Despite the occurrence of highly significant levels of sedation, there were no significant effects of nabilone on the continuous avoidance procedure. Two of these four subjects experienced an antianxiety effect from low (1 or 2 mg) nabilone doses. Four other subjects received comparatively lower doses of nabilone and performed on three behavioral tasks at intervals before and after drug: a recognition memory procedure, a task requiring spaced responding at a controlled rate, and a reaction time task. In these subjects there were no reliable effects on blood pressure or heart rate, no significant subjective effects on the POMS, and no antianxiety effects. Drug effects were also minimal on the three behavioral tasks.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117576     DOI: 10.1002/j.1552-4604.1981.tb02618.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2014-07-29       Impact factor: 4.492

2.  Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Authors:  Evan S Herrmann; Ziva D Cooper; Gillinder Bedi; Divya Ramesh; Stephanie C Reed; Sandra D Comer; Richard W Foltin; Margaret Haney
Journal:  Psychopharmacology (Berl)       Date:  2016-04-16       Impact factor: 4.530

Review 3.  Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; B Holmes
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

4.  Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2013-02-26       Impact factor: 7.853

5.  Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys.

Authors:  Marcus S Delatte; Carol A Paronis
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

6.  Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.

Authors:  Corneliu N Stanciu; Mary F Brunette; Nikhil Teja; Alan J Budney
Journal:  Psychiatr Serv       Date:  2021-02-03       Impact factor: 3.084

Review 7.  Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Authors:  Ainhoa Bilbao; Rainer Spanagel
Journal:  BMC Med       Date:  2022-08-19       Impact factor: 11.150

Review 8.  A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders.

Authors:  Keane Lim; Yuen Mei See; Jimmy Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-11-30       Impact factor: 2.582

9.  Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial.

Authors:  Swagata Dilip Tavhare; Rabinarayan Acharya; R Govind Reddy; Kartar Singh Dhiman
Journal:  Ayu       Date:  2019 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.